Background: This study investigated the effects of interleukin 23 (IL-23) on the production of cytokines (IL-1, IL-4, IL-10, and IL-17), the differentiation of Treg/Th17 and STAT3 (i.e., signal transducer and activator of transcription 3) in human decidual immune cells (DICs) during early pregnancy.
Methods: DICs were treated with recombinant human IL-23 and an antibody against IL-23 subunit p19. The differentiation of Treg and Th17 cells was detected by flow cytometry. Levels of IL-23 receptor (IL-23R), STAT3, and phosphorylated STAT3 (pSTAT3) was examined by Western blot. The production of IL1, IL4, IL10, and IL-17 in DICs was measured by ELISA.
Results: Exogenous recombinant human IL-23 significantly promoted the differentiation of Th17 cells from DICs, while anti-IL-23 antibody significantly promoted the differentiation of Treg cells from DICs. Consistent with the differentiation of Th17 and Tregs cells, levels of IL-1β and IL-17 correlated positively with IL-23 treatment, and anti-IL-23 antibody increased the secretion of IL-4 and IL-10 from DICs. Levels of pSTAT3, but not STAT3 or IL-23R, were significantly elevated by recombinant IL-23 treatment; anti-IL-23 antibody significantly decreased the levels of pSTAT3 and IL-23R in DICs.
Conclusions: IL-23 mediates the differentiation of Th17 and Treg cells and the production of associated cytokines in DICs. The potential mechanism likely involves the STAT3 pathway.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbrc.2015.11.118 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
is a leading cause of healthcare associated infection and an unacceptably high proportion of patients with infection die despite conventional antibiotic treatment. Host-directed immunotherapy has been proposed as an ideal treatment modality for infection to mitigate the underlying toxin-mediated pathogenic immune response while sparing protective gut microbes. Interleukin-23 monoclonal antibody inhibitors are used extensively to control pro-inflammatory Th17 immune pathways in psoriasis and inflammatory bowel disease that are similarly important during infection.
View Article and Find Full Text PDFSafety and Efficacy of Anti-IL-23 Monoclonal Antibody QX004N for Patients With Psoriasis: A Randomized Clinical Trial.
JAMA Dermatol
December 2024
Department of Dermatology and Venereology, the First Hospital of Jilin University, Changchun, China.
Article Synopsis
- Psoriasis is a chronic skin disease that currently lacks effective biologic treatment options, prompting the study of QX004N.
- This study was a two-part clinical trial in China, with part 1 focusing on healthy individuals and part 2 involving patients with moderate to severe plaque psoriasis.
- The trials assessed the safety, pharmacokinetics, and efficacy of QX004N, measuring outcomes like the improvement in psoriasis severity by week 12.
Psoriasis and inflammatory bowel disease: concomitant IMID or paradoxical therapeutic effect? A scoping review on anti-IL-12/23 and anti-IL-23 antibodies.
Therap Adv Gastroenterol
November 2024
IBD Centre, Gastroenterology Unit, Rho Hospital, ASST Rhodense, Rho, Italy.
Inflammatory bowel diseases (IBD) and psoriasis are chronic inflammatory conditions belonging to the heterogeneous group of immune-mediated inflammatory diseases (IMIDs). A significant bidirectional link between these two entities has been observed, conditioning an increased risk of IBD in patients with psoriasis and vice-versa. Biological therapies used for IBD may lead to the occurrence of psoriasis as a "paradoxical reaction.
View Article and Find Full Text PDFSuccessful Treatment of Adalimumab-Induced Paradoxical Skin Reactions in Pustulotic Arthro-Osteitis With Guselkumab.
Cureus
September 2024
Department of Anatomy, Miyazaki University, Miyazaki, JPN.
Article Synopsis
- * Patients using anti-TNF-α treatments, like adalimumab, often experience paradoxical skin reactions (PSRs), such as rashes and hair loss, necessitating a switch to alternative treatments.
- * Guselkumab, an anti-IL-23 treatment, not only avoids PSRs but also effectively manages PPP/PAO, and it is suggested as a preferable option over adalimumab for patients dealing with these conditions.
A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis-IL PSO (Italian Landscape Psoriasis).
Dermatol Ther (Heidelb)
November 2024
Dermatology Unit, IRCCS Humanitas Research Hospital, Via Alessandro Manzoni, 56, Rozzano, Milan, Italy.
Introduction: Guselkumab, a human monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), has shown efficacy in psoriasis and psoriatic arthritis. However, long-term real-world data on its effectiveness in patients with inadequate response to ustekinumab are limited. This study investigates guselkumab's long-term effectiveness and safety in patients with psoriasis with partial response to ustekinumab.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!